Abstract
Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and inevitably leads to an insidious functional deterioration, heart failure, and death [1]. Surgical aortic valve replacement (SAVR) is the current standard of care and is an accepted method to alleviate symptoms and prolong survival. For an array of reasons, approximately 30 % do not undergo SAVR [2]. However, since Dr. Alain Cribier pioneered the first transcatheter aortic valve replacement (TAVR) procedure in 2002 [3], this relatively new technique has been used extensively in over 40 countries accumulating to >50,000 implantations [4-19]. With results from the randomized PARTNER trial [20], TAVR has emerged as the standard of care for extremely high-risk or "inoperable" patients and is a valid alternative to surgery for selected high-risk but "operable" patients with symptomatic AS [21]. Currently, two different TAVR devices are widely available and used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) and the self-expanding Medtronic CoreValve™ (Medtronic, Minneapolis, MN). Both devices received CE Mark approval for European commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval in the USA in November 2011.
| Original language | English (US) |
|---|---|
| Title of host publication | Multimodality Imaging for Transcatheter Aortic Valve Replacement |
| Publisher | Springer-Verlag London Ltd |
| Pages | 3-17 |
| Number of pages | 15 |
| Volume | 9781447127987 |
| ISBN (Electronic) | 9781447127987 |
| ISBN (Print) | 1447127978, 9781447127970 |
| DOIs | |
| State | Published - Nov 1 2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
}
Transcatheter aortic valve implantation : Review of current evidence. / Généreux, Philippe; Leon, Martin B.
Multimodality Imaging for Transcatheter Aortic Valve Replacement. Vol. 9781447127987 Springer-Verlag London Ltd, 2014. p. 3-17.Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Transcatheter aortic valve implantation
T2 - Review of current evidence
AU - Généreux, Philippe
AU - Leon, Martin B.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and inevitably leads to an insidious functional deterioration, heart failure, and death [1]. Surgical aortic valve replacement (SAVR) is the current standard of care and is an accepted method to alleviate symptoms and prolong survival. For an array of reasons, approximately 30 % do not undergo SAVR [2]. However, since Dr. Alain Cribier pioneered the first transcatheter aortic valve replacement (TAVR) procedure in 2002 [3], this relatively new technique has been used extensively in over 40 countries accumulating to >50,000 implantations [4-19]. With results from the randomized PARTNER trial [20], TAVR has emerged as the standard of care for extremely high-risk or "inoperable" patients and is a valid alternative to surgery for selected high-risk but "operable" patients with symptomatic AS [21]. Currently, two different TAVR devices are widely available and used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) and the self-expanding Medtronic CoreValve™ (Medtronic, Minneapolis, MN). Both devices received CE Mark approval for European commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval in the USA in November 2011.
AB - Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and inevitably leads to an insidious functional deterioration, heart failure, and death [1]. Surgical aortic valve replacement (SAVR) is the current standard of care and is an accepted method to alleviate symptoms and prolong survival. For an array of reasons, approximately 30 % do not undergo SAVR [2]. However, since Dr. Alain Cribier pioneered the first transcatheter aortic valve replacement (TAVR) procedure in 2002 [3], this relatively new technique has been used extensively in over 40 countries accumulating to >50,000 implantations [4-19]. With results from the randomized PARTNER trial [20], TAVR has emerged as the standard of care for extremely high-risk or "inoperable" patients and is a valid alternative to surgery for selected high-risk but "operable" patients with symptomatic AS [21]. Currently, two different TAVR devices are widely available and used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) and the self-expanding Medtronic CoreValve™ (Medtronic, Minneapolis, MN). Both devices received CE Mark approval for European commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval in the USA in November 2011.
UR - http://www.scopus.com/inward/record.url?scp=84930014285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930014285&partnerID=8YFLogxK
U2 - 10.1007/978-1-4471-2798-7_2
DO - 10.1007/978-1-4471-2798-7_2
M3 - Chapter
AN - SCOPUS:84930014285
SN - 1447127978
SN - 9781447127970
VL - 9781447127987
SP - 3
EP - 17
BT - Multimodality Imaging for Transcatheter Aortic Valve Replacement
PB - Springer-Verlag London Ltd
ER -